132 related articles for article (PubMed ID: 3406022)
1. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma.
Cheung NK; Miraldi FD
Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022
[No Abstract] [Full Text] [Related]
2. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with GD2 specific monoclonal antibodies.
Cheung NK; Medof ME; Munn D
Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
[No Abstract] [Full Text] [Related]
4. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
[No Abstract] [Full Text] [Related]
5. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
6. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
7. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
8. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect of immunoconjugate composed of glucose-oxidase coupled to an anti-ganglioside (GD2) antibody on spheroids.
Heiss P; Bernatz S; Bruchelt G; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3177-8. PubMed ID: 9329630
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic application of radiolabelled monoclonal antibody UJ13A in children with disseminated neuroblastoma--a phase 1 study.
Kemshead JT; Goldman A; Jones D; Pritchard J; Malpas JS; Gordon I; Malone JF; Hurley GD; Breatnach F
Prog Clin Biol Res; 1985; 175():533-44. PubMed ID: 4039447
[No Abstract] [Full Text] [Related]
13. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
14. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study.
Cheung NK; Kushner BH; Yeh SJ; Larson SM
Prog Clin Biol Res; 1994; 385():319-28. PubMed ID: 7972227
[No Abstract] [Full Text] [Related]
15. Distribution of disialoganglioside GD2-antigen and binding of anti-GD2 antibodies on spheroids of neuroblastoma cell line.
Heiss P; Bermatz S; Wehnes H; Heinzmann U; Senekowitsch-Schmidtke R
Anticancer Res; 1997; 17(4B):3145-7. PubMed ID: 9329622
[TBL] [Abstract][Full Text] [Related]
16. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy].
Horwacik I
Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040
[TBL] [Abstract][Full Text] [Related]
17. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
18. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
Castel V; Segura V; CaƱete A
Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
[TBL] [Abstract][Full Text] [Related]
19. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
20. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]